Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Frailty Increases Hospitalization Rates in an Ambulatory Cohort of Patients With Cirrhosis: The North American Consortium for the Study of End-Stage Liver Disease 3 Prospective Cohort.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026

Same author

Erratum: Clinically relevant cut-points for changes in the Liver Frailty Index are associated with waitlist mortality in patients with cirrhosis.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2026

Same author

Erratum: The Liver Frailty Index enhances mortality risk prediction above and beyond MELD 3.0 alone.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2026

Same author

Correction to Higher Rate of Spontaneous Bacterial Peritonitis Recurrence With Secondary Spontaneous Bacterial Peritonitis Prophylaxis Compared With No Prophylaxis in 2 National Cirrhosis Cohorts.

The American journal of gastroenterology·2026

Same author

ACG Clinical Guideline: Hepatic Encephalopathy.

The American journal of gastroenterology·2026

Same author

Model for End-Stage Liver Disease-Lactate and Lactate Clearance in Critically Ill Cirrhosis Patients With Sepsis.

The American journal of gastroenterology·2026

Search research articles

Related Experiment Video

Updated: Apr 15, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Post-liver transplant hepatitis C therapy.

Robert S Rahimi¹, Jacqueline G O'Leary

¹Baylor Simmons Transplant Institute, Baylor University Medical Center, 3410 Worth St Suite 860, Dallas, TX, 75246, USA.

Current Treatment Options in Gastroenterology

|March 27, 2015

Summary

New direct-acting antiviral (DAA) therapies offer high sustained virologic response (SVR) rates for chronic hepatitis C virus (HCV) in liver transplant (LT) patients. These effective treatments are revolutionizing HCV management post-transplantation.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Published on: November 4, 2018

Related Experiment Videos

Last Updated: Apr 15, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Published on: November 4, 2018

Area of Science:

Hepatology
Virology
Pharmacology

Background:

Chronic hepatitis C virus (HCV) infection poses a significant challenge, particularly in liver transplant (LT) recipients.
Traditional therapies were limited by efficacy and side effect profiles.
Recent advancements in direct-acting antivirals (DAAs) have transformed HCV treatment paradigms.

Purpose of the Study:

To review the efficacy and tolerability of modern DAAs in patients post-liver transplantation.
To discuss the implications of these advancements for HCV management in LT recipients.
To explore the potential for peri-transplant DAA administration.

Main Methods:

Review of clinical trial data and pooled analyses of DAA regimens in post-LT patients.
Analysis of sustained virologic response (SVR) rates and treatment tolerability.
Discussion of specific DAA combinations including sofosbuvir, simeprevir, ledipasvir, and interferon-free regimens.

Main Results:

DAA cocktails achieve high SVR12 rates (>90%) in low-risk populations and are now successfully used off-label post-LT.
Specific regimens like sofosbuvir/simeprevir showed 87-90% SVR12, while paritaprevir/ritonavir/ombitasvir/dasabuvir achieved 97% SVR12 in early fibrosis.
Ledipasvir + sofosbuvir + ribavirin demonstrated >96% SVR12 in post-LT patients, including those with compensated cirrhosis.

Conclusions:

HCV treatment has entered a new era with DAAs offering high SVR rates comparable to non-transplant patients.
Non-decompensated post-LT patients can now achieve excellent outcomes with well-tolerated therapies.
The potential for peri-transplant DAA administration to prevent graft reinfection is an active area of investigation.